Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

中生北控生物科技股份有限公司
BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 8247)

ANNOUNCEMENT
(1) PROPOSED CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR; AND
(2) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the "**Board**") of directors (the "**Director(s)**") of Biosino Bio-Technology and Science Incorporation (the "**Company",** together with its subsidiaries, the "**Group**") hereby announces that Prof. Jin Tengchuan ("**Prof. Jin**") has tendered his resignation to the Company as an independent non-executive Director due to his wish to devote more time to his other commitments (the "**Resignation**"). The Resignation shall become effective upon (i) the conclusion of the extraordinary general meeting (the "**EGM**") to be convened by the Company on 20 November 2026; and (ii) the approval of the appointment of Mr. Pan Guangjin ("**Mr. Pan**") as an independent non-executive Director by the shareholders of the Company (the "**Shareholders**") at the EGM.

Prof. Jin has confirmed that he has no disagreement with the Board and there are no other matters relating to the Resignation that needs to be brought to the attention of the Shareholders or The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

PROPOSED APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that Mr. Pan has been nominated by the ninth session of the Board as a candidate for election at the EGM as an independent non-executive Director of the current session of the Board (the "**Proposed Appointment**"). Pursuant to the articles of association of the Company (the "**Articles of Association**"), the Proposed Appointment is subject to the approval by the Shareholders by way of an ordinary resolution at the EGM.

Mr. Pan has confirmed that (i) he met the independence criteria as set out in Rule 5.09 (1) to (8) of the Rules Governing the Listing of Securities on GEM of the Stock Exchange (the "**GEM Listing Rules**"); (ii) he has no past or present financial or other interest in the business of the Group or any connection with any core connected person (as defined under the GEM Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence at the time of his appointment.

Biographical details of Mr. Pan are set out as follows:

Mr. Pan Guangjin (潘光錦), aged 52, obtained a doctoral degree from the School of Medicine of Tsinghua University in 2005 and completed his postdoctoral research from the University of Wisconsin-Madison in 2008. Mr. Pan has extensive experience in regenerative medicine and stem cell research. Mr. Pan previously worked as an assistant researcher at the University of Wisconsin, a researcher and deputy director of the Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences. He is currently a director of the Centre for Regenerative Medicine and Health, Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences.

Mr. Pan will enter into a service agreement with the Company upon his appointment as an independent non-executive Director is approved by the Shareholders at the EGM. His term of service with the Company will take effect from the date of approval by the Shareholders at the EGM until the expiration of the term of the current session of the Board. His remuneration will be determined by the Board and the remuneration committee of the Company with reference to his duties and responsibilities, the performance of the Group and the prevailing market conditions.

Mr. Pan does not hold any directorship in any public companies where the securities of which are listed on any securities markets in Hong Kong or overseas in the last three years or any other positions with the Company and other members of the Group or have other major appointments and professional qualifications. He does not have, and is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations which are required to be disclosed pursuant to Part XV of the SFO. He does not have any relationship with other Directors, senior management, substantial or controlling shareholders of the Company as defined in the GEM Listing Rules.

Save as disclosed above, Mr. Pan has confirmed there is no other information required to be disclosed pursuant to Rule 17.50(2)(h) to (v) of the GEM Listing Rules and no matter regarding his appointment needs to be brought to the attention of the Shareholders.

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

The Board further announces that, in order to reflect the actual circumstances of the Company, the Board has resolved to propose amendments to Articles 19, 143 and 144 of the Articles of Association. The proposed amendments to the Articles of Association are subject to the approval by the Shareholders by way of a special resolution at the EGM.

The proposed amendments are set out below. The English translation is for reference only. In case of any inconsistency between the Chinese version and the English translation, the Chinese version shall prevail.

<table>
<tr><th>Before amendment</th><th>After amendment</th></tr>
<tr><td>Article 19:

Subject to the approval of the Economic Restructuring Office of the People's Government of Beijing Municipality evidenced by the approval document, "Jing Zheng Ti Gai Gu Han [2001] No. [25]", the Company may issue 70,017,528 ordinary shares. There is an aggregate of 70,017,528 ordinary shares issued to the Sponsors upon the incorporation of the Company with a nominal value of RMB1.00 each, representing 100% of the total number of ordinary shares of the Company. The share capital of the Company is RMB70,017,528.</td><td>Article 19:

Subject to the approval of the Economic Restructuring Office of the People's Government of Beijing Municipality evidenced by the approval document, "Jing Zheng Ti Gai Gu Han [2001] No. [25]", the Company may issue 70,017,528 ordinary shares. There is an aggregate of 70,017,528 ordinary shares issued to the Sponsors upon the incorporation of the Company with a nominal value of RMB1.00 each, representing 100% of the total number of ordinary shares of the Company. The share capital of the Company is RMB70,017,528.

<u>Upon the incorporation of the Company, the shareholding of each of the Sponsors was as follows:</u>
<table>
<tr><th><u>Name of Sponsor</u></th><th><u>Number of shares held</u></th><th><u>Shareholding percentage</u></th><th><u>Form of contribution</u></th><th><u>Date of contribution</u></th></tr>
<tr><td><u>Institute of Biophysics, Chinese Academy of Sciences</u></td><td><u>34,308,576</u></td><td><u>49.0%</u></td><td><u>Net assets</u></td><td><u>9 April 2001</u></td></tr>
</table>
</td></tr>
</table>

	Beijing Enterprises High-Tech Development Co., Ltd.* (北控高科技發展有限公司)	**24,506,143**	**35.0%**	**Cash**	**6 April 2001**
	Zhejiang Huangyan Fine Chemicals Group Co., Ltd.* (浙江黃岩精細化學品集團有限公司)	**5,951,492**	**8.5%**	**Cash**	**9 April 2001**
	Shanghai Lianchuang Venture Capital Co., Ltd.* (上海聯創創業投資有限公司)	**3,500,878**	**5.0%**	**Cash**	**5 April 2001**
	Zhu Yigui	**1,050,263**	**1.5%**	**Cash**	**9 April 2001**
	Fan Rong	**700,176**	**1.0%**	**Cash**	**9 April 2001**
	Total	**70,017,528**	**100%**	**/**	**/**

Article 143: The financial statements of the Company shall be prepared in accordance with PRC accounting standards and regulations. If required by the listing rules of the stock exchange where the company's shares are listed overseas, it shall also be prepared in accordance with either international accounting standards, or that of the place overseas where the shares of the Company are listed. If there is any material difference between the financial statements prepared respectively in accordance with the two accounting standards, such difference shall be stated in the financial statements. In distributing its profits after tax, the lower of the two amounts shown in the financial statements shall be adopted.	Article 143: The financial statements of the Company shall be prepared in accordance with PRC accounting standards and regulations. ~~If required by the listing rules of the stock exchange where the Company's shares are listed overseas, it shall also be prepared in accordance with either international accounting standards, or that of the place overseas where the shares of the Company are listed. If there is any material difference between the financial statements prepared respectively in accordance with the two accounting standards, such difference shall be stated in the financial statements. In distributing its profits after tax, the lower of the two amounts shown in the financial statements shall be adopted.~~

Article 144: Any interim results or financial information published or disclosed by the Company must be prepared and presented in accordance with PRC enterprise accounting standards and regulations. If required by the listing rules of the stock exchange where the company's shares are listed overseas, it shall also be prepared and presented in accordance with either international accounting standards or that of the place overseas where the shares of the Company are listed.	Article 144: Any interim results or financial information published or disclosed by the Company must be prepared and presented in accordance with PRC enterprise accounting standards and regulations. ~~If required by the listing rules of the stock exchange where the Company's shares are listed overseas, it shall also be prepared and presented in accordance with either international accounting standards or that of the place overseas where the shares of the Company are listed.~~

Save for the proposed amendments to the Articles of Association set out above, the other provisions of the Articles of Association remain unchanged.

GENERAL

A circular containing, among other things, (i) further details of the proposed appointment of independent non-executive Director; (ii) further details of the proposed amendments to the Articles of Association; and (iii) the notice of the EGM, together with the form of proxy, will be despatched to the Shareholders in due course.

* *For identification purposes only*

For and on behalf of the Board
Biosino Bio-Technology and Science Incorporation
Chen Peng
Chairman, President and Executive Director

Beijing, the PRC, 30 October 2026

As at the date of this announcement, the Board comprises:

Chairman, President and Executive Director
Mr. Chen Peng (陳鵬先生)

Vice Chairman and Executive Director
Mr. Li Zhonghua (李忠華先生)

Executive Director
Mr. Chen Zhengyong (陳正永先生)

Non-executive Director
Ms. Kang Rui (康睿女士)

Independent non-executive Directors
Prof. Shen Jiangang (沈劍剛教授), Mr. Fan Xiaoliang (范曉亮先生) and Prof. Jin Tengchuan (金騰川教授)

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, (1) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (2) there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Listed Company Information" page on the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.zhongsheng.com.cn.